We are live on ! Find out more
BG

Bollard Group Portfolio holdings

AUM $3.39B
1-Year Est. Return 1.06%
This Fund
S&P 500
This Quarter Est. Return
+6.94%
1 Year Est. Return
-1.06%
3 Year Est. Return
+72.63%
5 Year Est. Return
+112.03%
10 Year Est. Return
+415.67%
AUM
$2.85B
AUM Growth
+$169M
Cap. Flow
+$16.4M
Cap. Flow %
0.58%
Top 10 Hldgs %
65.16%
Holding
451
New
10
Increased
153
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
IT icon
Gartner
IT
+$5.11M
2
LMND icon
Lemonade
LMND
+$4.4M
3
TTD icon
Trade Desk
TTD
+$3.52M
4
BSX icon
Boston Scientific
BSX
+$2.93M
5
TRP icon
TC Energy
TRP
+$2.69M

Top Sells

Rank Stock Value
1
DKNG icon
DraftKings
DKNG
+$25M
2
LLY icon
Eli Lilly
LLY
+$4.8M
3
STAA icon
STAAR Surgical
STAA
+$1.43M
4
BPMC
Blueprint Medicines
BPMC
+$1.12M
5
TCP
TC Pipelines LP
TCP
+$337K

Sector Composition

Rank Sector Weight
1 Healthcare 46.71%
2 Consumer Discretionary 8.55%
3 Technology 8.03%
4 Communication Services 7.66%
5 Financials 6.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
401
DELISTED
Otonomy, Inc.
OTIC
$16K ﹤0.01%
6,442
– –
KIN
402
DELISTED
Kindred Biosciences, Inc.
KIN
$16K ﹤0.01%
3,129
– –
CPE
403
DELISTED
Callon Petroleum Company
CPE
$15K ﹤0.01%
399
– –
PRTK
404
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$15K ﹤0.01%
2,159
– –
NET icon
405
Cloudflare
NET
$101B
$14K ﹤0.01%
+200
New +$15.4K
PFIE
406
DELISTED
Profire Energy, Inc
PFIE
$14K ﹤0.01%
12,822
– –
KDP icon
407
Keurig Dr Pepper
KDP
$43B
$13K ﹤0.01%
368
+1
+0.3% +$32
FLXN
408
DELISTED
Flexion Therapeutics, Inc.
FLXN
$13K ﹤0.01%
1,406
– –
KRRO icon
409
Korro Bio
KRRO
$151M
$11K ﹤0.01%
22
– –
UMC icon
410
United Microelectronic
UMC
$47.5B
$11K ﹤0.01%
1,250
+550
+79% +$5.09K
DELL icon
411
Dell
DELL
$262B
$10K ﹤0.01%
235
– –
JNCE
412
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$10K ﹤0.01%
1,009
– –
LAB icon
413
Standard BioTools
LAB
$351M
$9K ﹤0.01%
1,975
– –
EWJ icon
414
iShares MSCI Japan ETF
EWJ
$22.1B
$8K ﹤0.01%
123
– –
NIO icon
415
NIO
NIO
$12.1B
$8K ﹤0.01%
+200
New +$10.2K
ZBH icon
416
Zimmer Biomet
ZBH
$18.4B
$8K ﹤0.01%
50
– –
ASIX icon
417
AdvanSix
ASIX
$555M
$6K ﹤0.01%
212
– –
CTMX icon
418
CytomX Therapeutics
CTMX
$714M
$6K ﹤0.01%
712
– –
HPQ icon
419
HP
HPQ
$24.6B
$5K ﹤0.01%
167
+1
+0.6% +$28
TTOO
420
DELISTED
T2 Biosystems, Inc
TTOO
$5K ﹤0.01%
1
– –
CNDT icon
421
Conduent
CNDT
$245M
$4K ﹤0.01%
530
– –
HPE icon
422
Hewlett Packard
HPE
$62.4B
$3K ﹤0.01%
161
+1
+0.6% +$14
OIH icon
423
VanEck Oil Services ETF
OIH
$2.01B
$3K ﹤0.01%
16
– –
OXY.WS icon
424
Occidental Petroleum Corp Warrants
OXY.WS
$32B
$3K ﹤0.01%
216
– –
ETTX
425
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$3K ﹤0.01%
1,448
– –
15 16
17
18 19

Similar funds

BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
VFCM
Valley Forge Capital Management Miami, Florida $3.38B AUM 15.93% 1-Year Est. Return
EFM
E Fund Management Guangzhou, China $3.37B AUM
DIA
Dana Investment Advisors Waukesha, Wisconsin $3.35B AUM 29.65% 1-Year Est. Return
5NCM
59 North Capital Management Houston, Texas $3.35B AUM 22.14% 1-Year Est. Return

Bollard Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bollard Group held 451 positions worth $2.85B, up 6.3% from $2.69B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Bollard Group's Q1 2021 filing shows 10 new, 153 increased, 16 reduced and 14 closed positions. Its largest new stake was Lemonade: 34,100 shares worth $3.18M. The largest sale was DraftKings, an estimated $25M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 46% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Bollard Group's largest Q1 2021 buy was Lemonade: 34,100 shares worth $3.18M.
  • Bollard Group added most to Gartner in Q1 2021, an estimated $5.11M increase.
  • Bollard Group's biggest Q1 2021 reduction was Eli Lilly, cutting an estimated $4.8M.
  • Bollard Group fully exited DraftKings in Q1 2021, selling an estimated $25M.
  • Bollard Group's ten largest holdings make up 65% of its $2.85B portfolio in Q1 2021.
  • Bollard Group opened 10 new positions and closed 14 in Q1 2021.
  • Bollard Group's portfolio value rose 6.3% quarter-over-quarter to $2.85B.

Based on Bollard Group's 13F filing for Q1 2021, filed 11 May 2021.